Researchers announced a breakthrough advance in a world-first international clinical trial of a new drug to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma that is refractory or resistant to current chemotherapies.
Recent laboratory findings provide novel insight into potential new therapeutic approaches for triple-negative breast cancer, a particularly difficult-to-treat and aggressive form of the disease.
Atezolizumab may substantially change treatment strategies for patients with refractory lung cancer, according the first efficacy results from the POPLAR and BIRCH studies, which studied the PD-L1 antibody across treatment lines.
Current results from a clinical trial comparing a combination of two targeted therapies with a single-agent treatment for advanced melanoma has shown patients are living significantly longer with the combination therapy.
Brentuximab vedotin is proven an effective and safe first course of treatment for older patients with Hodgkin lymphoma who are not candidates for chemotherapy.
Researchers are working on a way to use artificial intelligence to predict a patient's response to two common chemotherapy drugs used to treat breast cancer: paclitaxel and gemcitabine.
Researchers have shown that a certain protein becomes overabundant in pancreatic neuroendocrine tumors, allowing them to thrive. They also found that pairing a synthetic compound with an existing drug provides a more effective anticancer punch than a single drug.
Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis - European Journal of CancerSeptember 04, 2015
A recent study examined the cardiotoxicity of anthracyclines in patients with breast cancer.
Researchers have pinpointed a novel genetic biomarker responsible for the progression of many breast and prostate cancers.
Ion channel blockers, drugs commonly used to treat cardiac, neurologic, and psychiatric disorders, might prove useful in cancer therapy, according to new research.
By surrounding molecules of paclitaxel with self-assembling spheres composed of amino acids, researchers doubled tumor exposure to the drug and reduced its effects on healthy tissue.
An increasing number of oncology/hematology treatments will consist of oral oncolytics, and oncology programs are needed to manage the treatment of patients following these regimens.
The discovery of an enzyme that facilitates the spread of breast cancer may enable clinicians to prevent secondary cancer.
A combination approach utilizing three differing anticancer drug classes could hold the key to besting glioblastoma.
Drugs that are more commonly used to treat melanoma can also be use to help some individuals with lung cancer, research indicates.
Peripheral neuropathy associated with nab-paclitaxel among chemotherapy-naïve patients can be managed by dose interruptions and modifications.
A phase 3 trial of brentuximab vedotin (BV) showed that adults with hard-to-treat Hodgkin lymphoma given BV after stem cell transplantation survived without the disease progression for twice as long as when a placebo was administered.
Acute lymphoblastic leukemia (ALL) has been found to have two distinct subtypes, and evidence indicates that roughly 13% of ALL cases may be successfully treated with targeted drugs used in the treatment of lymphomas in adults.
Low doses of metformin and a gene inhibitor known as BI2536 can successfully halt the growth of late-stage prostate cancer tumors.
According to a new study, patients with diabetes become less adherent to their diabetes medication regimen following a diagnosis of cancer.
In treatment for metastatic breast cancer, eribulin is effective as a first-, second-, or third-line chemotherapy regimen.
How should a fibrin overgrowth on an internal catheter be managed when there is no blood return from the implanted port?
A drug used to treat Lou Gehrig's disease has also been found to improve the effectiveness of radiation therapy when administered to laboratory models with melanoma that metastasized to the brain.
Researchers have uncovered how melanoma becomes resistant to a promising new drug combination utilizing BRAF+MEK inhibitors after an initial period of tumor shrinkage.
Effectiveness of nanoparticle drugs was hindered by tumor microenvironment in triple-negative breast cancerJanuary 29, 2015
Nanoparticle drugs were considered to be a potential silver bullet against cancer, but they have not produced the anticipated improvement in overall survival rates.
Sunitinib, an agent approved for use in several cancers, could prove useful in treatment of thymic carcinoma when traditional chemotherapy fails.
Previously, patients with advanced colorectal cancer driven by a mutated version of the BRAF gene have had limited treatment options, but results from a multicenter clinical trial suggest a new option.
The current classification system for colorectal cancer, based on genetic profiles, cannot be used to predict drug responses to FOLFIRI.
What are the treatment options for recurrent metastatic HER2-positive breast cancer after trastuzumab therapy?
A PARP inhibitor in oral tablet form, given in combination with chemotherapy, was deemed safe for heavily pretreated patients with ovarian cancer.
- Risk of Some Cancers Modestly Increased in Persons Who Had Herpes Zoster
- Blood Test Indicates Breast Cancer Tumors Developed Resistance to Hormone Treatment
- Breakthrough Advance Announced in International Blood Cancer Drug Trial
- Gut Bacteria Can Dramatically Amplify Cancer Immunotherapy
- Survival for Follicular, Diffuse Large B-cell Lymphomas Improving in Europe
- Breastfeeding Associated With A Reduced Risk of Aggressive Breast Cancer
- Hospitals Should Enact Bereavement Programs, Researchers Urge
- Physical Activity Communications Should be Part of Oncology Care Clinic Visits With Patients
- Communication Practices of Many US Physicians May Be Discouraging HPV Vaccination
- Navigation Program Tackles Cancer Care on Two Fronts
- Protein Biomarker Assays for Diagnosing Thyroid Cancer May Show Inaccurate Readings
- Cancer Prehabilitation and Rehabilitation: What Will It Take for These Services to Catch On?
- New Model for Breast Cancer Risk in Hispanic Women Is the First to be Based Exclusively on Data From Hispanic Women
- Blood Sample New Way of Detecting Cancer
- Liquid Biopsy of Cerebrospinal Fluid More Effective in Managing Brain Tumors
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|